| Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. (NCT05311943) | Shenzhen Second People's Hospital | 2022-07-01 |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (NCT05143840) | University of Alabama at Birmingham | 2022-04-22 |
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (NCT04006847) | Milton S. Hershey Medical Center | 2020-09-14 |
| Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia (NCT04147533) | Masaryk University | 2020-06-16 |
| Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP) (NCT04160546) | Fundacion CRIS de Investigación para Vencer el Cáncer | 2020-01-17 |
| Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors (NCT03610971) | H. Lee Moffitt Cancer Center and Research Institute | 2019-11-19 |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase (NCT04126681) | Ascentage Pharma Group Inc. | 2019-10-21 |
| Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients (NCT03885830) | UNC Lineberger Comprehensive Cancer Center | 2019-06-20 |
| Nilotinib for First-line Newly Diagnosed CML-CP Patients (NCT03942094) | Shenzhen Second People's Hospital | 2019-06-01 |
| A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation (NCT03883087) | Ascentage Pharma Group Inc. | 2019-04-08 |
| Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia (NCT03882281) | Ascentage Pharma Group Inc. | 2019-03-25 |
| Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) (NCT03722420) | Il-Yang Pharm. Co., Ltd. | 2018-12-28 |
| A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs (NCT03459534) | Il-Yang Pharm. Co., Ltd. | 2018-06-25 |
| Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia (NCT03079505) | Hamad Medical Corporation | 2017-08-03 |
| Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose (NCT03933852) | University of Jena | 2015-07-08 |
| Efficacy and Safety of Nilotinib in CML-CP (NCT03332511) | Seoul National University Hospital | 2013-05-06 |
| Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan (NCT02977312) | Hikma Pharmaceuticals LLC | 2012-08-01 |